with a population of 2.75 million people. Patients with a primary diagnosis of valvular or congenital heart disease were excluded. The project, which began enrolling patients in 1995, is approved annually by the Ethics Review Board of each participating center. Patients signed informed consent to allow clinical follow-up. Demographic and clinical data of enrolled patients were prospectively collected at the time of the initial diagnostic procedure in the catheterization laboratories of the Foothills Hospital and Holy Cross Hospital in Calgary as well as the University of Alberta Hospital and the Royal Alexandra Hospital in Edmonton, Alberta, Canada. Coronary angiographic data were recorded with use of Heartview software (Duke Medical Center, Durham, NC). Left ventricular ejection fraction (LVEF) was measured in each center by computerized edge detection methods at the time of the diagnostic angiographic procedure. In the event that measurement was not done (31% of cases), the operator performing the diagnostic procedure made a visual estimate of the LVEF. Other incomplete clinical data were supplemented by corresponding International Classification of Disease, 9th Revision, Clinical Modification coded diagnoses from the administrative databases of the 4 centers with use of a validated data enhancement method. 5 Data were transmitted from participating centers by a secure encrypted internet link to the data center at the University of Alberta Hospital. Vital status was determined semiannually from the Province of Alberta Department of Vital Statistics.
Definitions
Two-vessel and 3-vessel disease was defined as presence of 2 or 3 major epicardial coronary arteries with ≥70% diameter stenosis, determined visually by the cardiologist performing the first diagnostic catheterization procedure during the study period 1995-1998. Left main disease was defined as ≥50% diameter stenosis in the left main coronary artery. Patients were categorized into treatment groups according to the first treatment type within the first year after enrollment. This definition was instituted as a result of waiting periods for revascularization procedures in the province. The medical therapy group was therefore defined as patients with no coronary revascularization procedure within 1 year of the index angiographic procedure. Revascularized patients were included in the PCI or CABG groups if they had one of these procedures as the first intervention within 1 year of the index angiographic procedure. Events were assigned for any given treatment modality received at the time and not for intention to treat.
Statistical analysis
Baseline comparisons of clinical characteristics across treatment groups were made by χ 2 tests for categorical variables and analysis of variance for continuous variables. KaplanMeier analysis was used to present unadjusted 5-year survival for each of the treatment groups. Cox proportional hazards models were then used to determine risk-adjusted survival for clinical characteristic and comorbidity and for each of the treatment groups. These included age, sex, history of diabetes mellitus, hyperlipidemia, hypertension, liver or gastrointestinal disease, malignancy, chronic obstructive pulmonary disease, serum creatinine level >200 mmol/L, cerebrovascular disease, peripheral vascular disease, congestive heart failure, prior myocardial infarction, prior coronary revascularization procedures, coronary anatomy severity, and LVEF. Comorbid conditions were deemed to be present if they were identified as such by the referring cardiologist or in the hospital record. The indication for the catheterization procedure (acute or recent myocardial infarction, unstable angina, stable angina, or other) was also included. Risk-adjusted hazard ratios were calculated for the following treatment comparisons: CABG/medical, PCI/medical, and CABG/PCI. Risk-adjusted treatment comparisons were also made within each level of coronary anatomy. The Duke coronary severity system was used in all risk-adjustment procedures. All analyses were conducted with use of SPSS version 10.0 (SPSS, Chicago, Ill).
Results

Clinical characteristics
Of the 23,877 patients who underwent coronary angiography for presumed CAD in the province of Alberta in 1995-1998, 22,690 were Alberta residents, and of these 11,661 (51%) had MVD. Mean time from catheterization to CABG was 70 ± 82 days and to PCI 22 ± 48 days. Mean follow-up was 2.7 ± 1.3 years (median 2.7 years). Patients selected for medical therapy were older. The group treated with CABG contained the lowest proportion of women. Patients in the CABG group were also less likely to have had a previous myocardial infarction (MI) than any other group and were less likely to have had previous CABG or PCI. Type 2 diabetes, hypertension, and renal dysfunction were observed least frequently in the PCI group. However, PCI was the treatment performed most frequently in the setting of acute or recent MI and least frequently in the setting of stable angina (Table I ). Thirty percent of PCI patients received at least 1 stent.
Analysis of coronary anatomy and LV function (Table  II) indicated that among patients treated with a revascularization procedure 2-vessel CAD was more prevalent in the PCI group, whereas CABG patients had a higher incidence of left main and 3-vessel CAD with proximal left anterior descending (LAD) stenosis. Medically treated patients were more likely to have severe LV dysfunction.
Coronary anatomy, treatment, and 5-year survival ( Figure 1) Cumulative 5-year survival ranged from 91.4% in the group with 2-vessel CAD to 87.9% in those with 3-vessel CAD and 82.8% in patients with left main disease. Unadjusted survival was similar in the CABG (91.4%) and PCI (91.9%) groups but was significantly lower in the group selected for medical therapy (82.9%, P < .0001). Survival for patients with 2-vessel CAD was CABG 91.6%, PCI 93.6%, and medical 88.5% (P < .0001). In those with 3-vessel CAD survival was CABG 92.1%, PCI 91.0%, and medical 82.8% (P < .0001). Finally, in those with left main CAD survival was 89.5% with CABG, 80.5% with PCI, and 69.5% with medical therapy (P < .0001).
Clinical characteristics and survival (Figure 2)
Women were at higher risk than men. Diabetes, malignancy, chronic obstructive pulmonary disease, peripheral vascular disease, MI, and congestive heart failure were independent predictors of worse outcome. The hazard also increased with increasing Duke coronary severity and decreasing left ventricular function. An indication for the procedure of acute or recent MI was also an independent predictor of increased risk. Outcome comparison of revascularization versus medical therapy
Risk-adjusted hazard ratio analysis comparing cumulative 5-year mortality of patients treated with PCI, CABG, and medical therapy indicate significantly lower hazard ratio for 5-year mortality for treatment with CABG (hazard ratio 0.53, 95% confidence interval [CI] 0.46-0.61; P < .001) as well as PCI (hazard ratio 0.65, 95% CI 0.56-0.74; P < .001) compared with medical therapy in the overall MVD cohort. A more complex picture emerges with comparison of treatment strategies in the broad coronary anatomy groups and Duke subgroups.
In the entire group with 2-vessel disease, an association between treatment and survival was found only for PCI-treated patients. PCI treatment appeared to have a similar impact in the overall group with 3-vessel CAD (PCI vs medical hazard ratio 0.61, 95% CI 0.51-0.74; P < .001). A similar association was observed with CABG compared with medical therapy in the 3-vessel CAD patients (CABG vs medical hazard ratio 0.55, 95% CI 0.46-0.66). In the presence of left main disease, only treatment with CABG was associated with a lower risk compared with medical therapy (P < .001).
Detailed treatment comparison of revascularization versus medical therapy by Duke coronary severity groups ( Figure 3 ) reveals an association between CABG and survival in patients with left main CAD and all subAmerican Heart Journal July 2001
Figure 1
Kaplan-Meier analysis of cumulative survival to 5 years of patients enrolled in APPROACH between January 1995 and December 1998, stratified by treatment.
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sets with 3-vessel CAD. An association in all 3-vessel CAD subgroups is also observed for PCI treatment, an association that extends to those with 2-vessel CAD with severe (95%) proximal LAD disease.
Outcome comparison of revascularization strategies
Risk-adjusted comparison reveals a lower risk of mortality up to 5 years for treatment with CABG compared with PCI for the entire group (hazard ratio 0.81, 95% CI 0.68-0.96; P = .019). As Figure 3 indicates, this overall advantage favoring CABG is largely related to the low hazard ratio for CABG in the subgroup with severe left main disease.
Outcome in patients with diabetes mellitus
Cumulative 5-year survival was 82.9% in the 2654 patients with MVD who had diabetes mellitus. By treatment group, survival was as follows: medical therapy 76.6%, PCI 87.3%, and CABG 87.4%.
Discussion
This study examines survival in patients with MVD in a large multicenter regional setting in a transitional period of increasing stent utilization. [6] [7] [8] An association is observed between treatment with CABG as well as PCI and favorable cumulative survival up to 5 years compared with medical therapy alone, after adjustment for important risk factors and comorbid conditions.
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Figure 2
Adjusted hazard ratios for mortality for all recorded baseline characteristics and comorbid conditions. GI, Gastrointestinal; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease; PVD, peripheral vascular disease; CHF, congestive heart failure.
Figure 3
Cox proportional hazard comparison of 5-year mortality in 11,661 patients with MVD enrolled in the APPROACH registry from January 1995 to December 1998.
Outcome after CABG
Early registries demonstrated a higher survival rate in patients treated with CABG compared with those treated medically, with survival in patients with 3-vessel CAD being linked to completeness of revascularization. [9] [10] [11] Randomized trials comparing CABG and medical therapy showed mixed results. 12, 13 Long-term survival was improved by surgery only in those with 3-vessel CAD and impaired LV function or 2-vessel CAD with a severe proximal LAD stenosis. [14] [15] [16] [17] [18] Our cumulative 5-year survival observations are in accordance with these findings. Although surgically treated patients with 3-vessel and left main CAD clearly have a lower risk-adjusted mortality than do similar patients treated medically, there appears to be no significant survival benefit to initial treatment with CABG compared with medical therapy in those with 2-vessel CAD even in the presence of severe proximal LAD disease.
These findings are also similar to those of a Duke Medical Center Registry of 9263 patients treated between 1984 and 1990, which revealed a significant 5-year survival benefit of CABG over medical therapy in patients with 3-vessel CAD, as well as a small survival advantage in those with 2-vessel CAD. 19 At 10-year follow-up, treatment with CABG was associated with a significant survival advantage over medical therapy in MVD patients in all Duke coronary severity subgroups except those without at least one 95% stenosis. 20 The lack of an adjusted survival difference in the current study between CABG and medical therapy, in 2-vessel CAD patients, including those with severe proximal LAD stenosis, may be related to advances in medical therapy that have occurred since completion of the Duke study. 21, 22 Outcome after PCI Uncontrolled studies demonstrated sustained clinical improvement in long-term outcome with multivessel PCI, 23, 24 especially when complete revascularization could be achieved. 25, 26 Randomized data comparing long-term survival after PCI and medical therapy are sparse. Small sample size in the Veterans Affairs Angioplasty Compared to Medicine (ACME) trial precluded the possibility of a survival comparison. 27 The Atorvastatin Versus Revascularization Treatments (AVERT) trial, which reported a lower incidence of ischemic events with high-dose atorvastatin compared with PCI, enrolled just 148 patients with 2-vessel CAD and excluded those with 3-vessel CAD.
Our observations with respect to the risk with PCI compared with medical treatment confirm those of the earlier Duke Registry with respect to survival differences favoring PCI in all coronary severity groups up to 3-vessel CAD. 19 However, our data indicate an extension of risk reduction with PCI to those with 3-vessel disease, including those with proximal LAD (including 95% stenosis) disease. This extension of apparent benefit is likely related to introduction of stents to the field of interventional cardiology, which has markedly reduced the rates of restenosis and abrupt closure, [28] [29] [30] [31] advances in balloons and guide wires, as well as refinement in patient selection and interventional strategies stemming from an added 10 years of cumulative operator experience. The lack of a difference in patients with less severe 2-vessel CAD parallels the comparison between CABG and medical therapy, and may, again, be related to advances in medical therapy that may have favorably influenced survival in the medically treated group.
CABG versus PCI
Early randomized trials of CABG versus percutaneous transluminal coronary angioplasty, reporting similar outcome with surgery and PCI, were all underpowered to detect differences in survival. 1, 2, 32 Three larger trials, with a combined sample size of 3894 patients, confirmed the survival equivalence of the 2 treatment strategies. 3, 4, 33 A recently reported study of 450 patients randomized to PCI versus CABG in the stent era revealed significantly higher survival in the group assigned to PCI (96.9% vs 92.5%, P < .017) at 18-month follow-up. 34 The only finding suggestive of worse outcome with PTCA was in the Bypass Angioplasty Revascularization Investigation (BARI), in which diabetic patients assigned to percutaneous transluminal coronary angioplasty had significantly lower survival at 5 years than did those randomized to CABG. Interestingly, our data with respect to the diabetic population with MVD indicate similar survival rates in those treated with PCI and CABG, suggesting that appropriate case selection to a PCI strategy can result in excellent longterm survival in diabetic patients.
The applicability of knowledge gained from these trials to current treatment of unselected patients with MVD in clinical practice is limited by highly selected study populations. All trials excluded patients with previous revascularization procedures, whereas some excluded any patients with total coronary occlusions. 1,2 All but one were conducted before the current era of stenting.
The concern of generalizability was addressed by the Duke Registry studies reporting on an unselected population and more recently by the BARI Registry, which showed equivalent survival up to 7 years in patients treated with PCI and CABG, findings attributed to appropriate case selection for PCI, with patients undergoing PCI having more favorable coronary anatomy, resulting in higher procedural success and thus better outcome. 35 The current study extends knowledge regarding longterm survival in patients with MVD to reflect implementation of current technical and procedural advances. The high survival observed with PCI in the stent era is quite likely a function of reduction in major cardiac events, especially the need for repeat target vessel revascularization, recently observed with a temporal increase in the utilization of stents in another large Canadian prospective registry. 36 The hazard ratio favoring CABG compared with PCI is almost entirely a function of benefit in the severe left main disease group. The suggested equivalence of CABG and PCI in the setting of 2-vessel and 3-vessel disease is compelling. Admittedly, we cannot rule out an effect of clinical selection, whereby patients with the most favorable anatomy are selected for PCI, with the remaining patients suitable for revascularization being referred for CABG and those with most untoward anatomy being treated medically.
Study limitations
The major limitation of this study lies in its nonrandomized nature and the inherent patient selection that operates in clinical practice. It is probable that those with the least favorable clinical or anatomic characteristics are selected for medical therapy and those with the best characteristics are selected for revascularization. Although our risk adjustment deals with this problem to some extent, important characteristics such as diffuseness of CAD are missing from the model. We thus strongly caution against drawing inferences on treatment efficacy from these data. Rather, these results from a population-based study demonstrate the prognosis associated with treatment received.
Furthermore, with a waiting list for revascularization, the most unstable patients waiting may have died, rendering the revascularization group to be less unstable and to have a lower mortality rate. Risk adjustment would have corrected for this at least in part. This phenomenon raises the possibility that revascularization in the province should be considered earlier and more broadly. Finally, with incomplete data on concomitant medical therapies and lipids, we are uncertain of secondary prevention therapy utilization in the 3 treatment groups.
Conclusions
Capturing the entire spectrum of clinical practice in a geographic region, this prospective registry of patients undergoing cardiac catheterization and found to have MVD demonstrates an association with favorable survival to 5 years with CABG and PCI compared with medical therapy. Risk-adjusted survival is also similar in patients with 2-and 3-vessel CAD selected for PCI compared with CABG. These observations likely represent a combination of appropriate patient selection factors as well as possible true differences in the efficacy of the treatment strategies. The findings must therefore be corroborated by long-term follow-up from randomized trials comparing PCI and adjunctive contemporary antiplatelet therapy with CABG as well as with current optimal medical therapy.
